



CLAIMS

1. A compound comprising at least one nuclear payload and at least one nuclear receptor-targeting epitope; provided that when the compound comprises one nuclear payload and one nuclear receptor-targeting epitope:
 - the nuclear receptor-targeting epitope is not a peptide, protein, nanoparticle or antibody;
 - and
 - when the nuclear receptor-targeting epitope is an androgen receptor-targeting epitope or an estrogen receptor-targeting epitope, the nuclear payload is not doxorubicin, or an analog thereof, and is not a hydroxamic acid which binds histone deacetylase (HDAC).
2. A compound comprising at least one nuclear payload which binds to a catalytic domain of poly(ADP-ribose) polymerase (PARP) and at least one nuclear receptor-targeting epitope.
3. The compound of claim 1 or 2, wherein at least one nuclear receptor-targeting epitope is a nuclear steroid receptor-targeting epitope.
4. The compound of any preceding claim, wherein the nuclear payload is bonded to one nuclear receptor-targeting epitope via a non-bioleavable linking moiety and one or more nuclear receptor-targeting epitope(s) via a bioleavable linking moiety.
5. The compound of any preceding claim, wherein the compound comprises at least one nuclear payload which binds to a protein involved in the DNA damage repair process.
6. The compound of any preceding claim, wherein the compound comprises at least one nuclear payload which binds poly(ADP-ribose) polymerase (PARP), DNA-dependent protein kinase (DNA-PK), histone deacetylase (HDAC), enhancer of zeste homolog 2 (EZH2), histone acetyltransferase (HAT), methyltransferase, a bromodomain, myelin transcription factor 1 (MYT1), p53, melanocyte-stimulating hormone (MSH), mutL homolog (MLH), ERCC1, apurinic/apyrimidinic endonuclease 1 (APE1), topoisomerase I (Topo I), topoisomerase II (Topo II), Wee1, checkpoint kinase1 (Chk1), checkpoint kinase2 (Chk2), ataxia telangiectasia (ATR), or ataxia-telangiectasia mutated (ATM).
7. The compound of any preceding claim, wherein the nuclear payload comprises olaparib (AZD-2281), Olaparib TOPARP-A, rucaparib (AG014699, PF-01367338), niraparib, talazoparib (BMN-673), veliparib (ABT-888), CEP 9722, E7016, BGB-290, 3-aminobenzamide, methoxyamine, CC-115, MSC2490484A, AZD6738, VX-970, AZD0156, GDC-0575, MK-8776, LY2606368, AZD1775, belotecan, CRLX101, irinotecan, LMP 400, LMP 776, NKTR-102, topotecan, doxorubicin, epirubicin, etoposide, idarubicin, mitoxantrone, teniposide, vorinostat, romidepsin (Istodax), chidamide, panobinostat (Farydak), belinostat (PXD101), panobinostat (LBH589), valproic acid (as Mg valproate), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat

(MS-275), SB939, resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), HBI-8000, kevetrin, CUDC-101, AR-42, CHR-2845, CHR-3996, 4SC-202, CG200745, ACY-1215, ME-344, sulforaphane, tazemetostat, MAK638, CPI-1205), DS-3201b, anacardic acid, MG149, C646, S-adenosyl methionine, JQ1, I-BET 151 (GSK1210151A), I-BET 762 (GSK525762), OTX-015, TEN-010, CPI-203, CPI-0610, olinone, LY294002, or an analog thereof.

8. The compound of claim 2, wherein the compound comprises at least one nuclear payload which binds to a catalytic domain of poly(ADP-ribose) polymerase (PARP).
9. The compound of claim 2, wherein the catalytic domain comprises a conserved HYE motif.
10. The compound of any preceding claim, wherein the compound comprises at least one nuclear payload which binds to a poly(ADP-ribose) polymerase (PARP) with an IC_{50} of less than about 500 nM.
11. The compound of claim 8, wherein the PARP comprises PARP-1 and/or PARP-2, or a variant thereof.
12. The compound of any preceding claim, wherein the compound is of Formula I or II:



wherein:


A is a nuclear payload;

m is 1, 2 or 3;


each B is independently a nuclear receptor-targeting epitope; and

each L is independently a covalent bond or a linking moiety.


13. A compound of Formula III, IV, V or VI, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof:



III



IV



wherein:

each R^1 , R^2 , R^3 and R^4 is independently $-L-(B)_m$, hydrogen, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, C_{3-10} cycloalkyl, heterocyclyl, aryl, heteroaryl, $-C(=O)R^5$, $-C(=O)OR^5$, $-C(=O)NR^5R^6$, $-S(=O)_{1-2}R^5$, $-S(=O)_{1-2}NR^5R^6$, $-NR^5S(=O)_{1-2}R^6$ or $-C=NOR^5$, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl of R^1 , R^2 , R^3 and R^4 are independently optionally substituted with one or more R^{10} as valency permits;

m is 1, 2, or 3;

each L is independently a covalent bond or a linking moiety;

each B is independently a nuclear receptor-targeting epitope;

each R^{10} is independently halo, cyano, nitro, $-OR^7$, $-SR^7$, $-SF_5$, $-NR^7R^8$, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, C_{3-10} cycloalkyl, heterocyclyl, aryl, heteroaryl, $-C(=O)R^7$, $-C(=O)OR^7$, $-OC(=O)OR^7$, $-OC(=O)R^7$, $-C(=O)NR^7R^8$, $-OC(=O)NR^7R^8$, $-NR^7C(=O)NR^7R^8$, $-S(=O)_{1-2}R^7$, $-S(=O)_{1-2}NR^7R^8$, $-NR^7S(=O)_{1-2}R^8$, $-NR^7S(=O)_{1-2}NR^7R^8$, $-NR^7C(=O)R^8$, $-NR^7C(=O)OR^8$ or $-C=NOR^7$, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl of R^{10} are independently optionally substituted with one or more halo or C_{1-12} alkyl optionally substituted by oxo, halo, hydroxyl or amino as valency permits; and


each R^5 and R^6 is independently hydrogen, deuterium, C_{1-12} alkyl or C_{3-12} cycloalkyl, optionally substituted with oxo, halo, hydroxyl or amino as valency permits; or R^5 and R^6 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C_{1-12} alkyl optionally substituted by oxo, halo, hydroxyl or amino;

each R^7 and R^8 is independently hydrogen, deuterium or C_{1-12} alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits; or R^7 and R^8 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C_{1-12} alkyl optionally substituted by oxo, halo, hydroxyl or amino; and

R^9 is hydrogen or R^2 ;

provided that at least one R^1 , R^2 , R^3 and R^4 is $-L-(B)_m$.

14. A compound of Formula IIIB, IVA, VB or VIA, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof:



wherein:


R² is -L-(B)_m;

m is 1, 2, or 3;

L is a covalent bond or a linking moiety; and

each B is independently a nuclear receptor-targeting epitope.

15. The compound of any one of claims 12-14, wherein at least one L is a non-biocleavable linking moiety.
16. The compound of any one of claims 12-14, wherein at least one L is an acid-labile linking moiety.
17. The compound of any one of claims 12-16, wherein the linking moiety is alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene or heterocycloalkylene; wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, may optionally comprise an arylene, heteroarylene, cycloalkylene or heterocycloalkylene; and further wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene or heterocycloalkylene is independently optionally substituted with one to five substituents independently selected from oxo, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkyl.
18. The compound of any one of claims 12-17, wherein the linking moiety is of the formula:



wherein:

each of Y¹, Y², and Y³ are independently a bond, -NR¹¹-, -O-, -S(O)₀₋₂-, -NR¹¹C(O)-, -C(O)NR¹¹-, -NR¹¹S(O)₂-, -S(O)₂NR¹¹-, -CR¹²=N-NR¹¹-, -NR¹¹-N=CR¹²-, -C(O)-, arylene, heteroarylene, cycloalkylene or heterocycloalkylene; wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene or heterocycloalkylene is independently optionally substituted with one to five substituents independently selected from oxo, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkyl;

each R¹¹ is independently C₁₋₄ alkyl, C₁₋₄ haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

each R¹² is independently C₁₋₄ alkyl, C₁₋₄ haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

n' and m' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

19. The compound of any one of claims 12-18, wherein at least one linking moiety comprises a hydrazone linkage.
20. The compound of any preceding claim, wherein the at least one nuclear receptor-targeting epitope is a nuclear steroid receptor-targeting epitope.
21. The compound of any preceding claim, wherein the at least one nuclear receptor-targeting epitope is independently selected from an estrogen receptor-targeting epitope, glucocorticoid receptor-targeting epitope, progesterone receptor-targeting epitope or androgen receptor-targeting epitope.
22. The compound of any preceding claim, wherein the at least one nuclear receptor-targeting epitope independently comprises an epitope derived from an androgen receptor agonist, an androgen receptor antagonist, a selective androgen-receptor modulator (SARM), an estrogen receptor agonist, an estrogen receptor antagonist, a selective estrogen receptor modulator (SERM), a glucocorticoid receptor antagonist, a glucocorticoid receptor agonist, a selective glucocorticoid receptor modulator (SGRM), a progesterone receptor antagonist, a progesterone receptor agonist, a selective progesterone receptor modulator (SPRM), or a combination thereof.
23. The compound of any preceding claim, wherein the at least one nuclear receptor-targeting epitope independently comprises an epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof.
24. The compound of any preceding claim, wherein at least one nuclear receptor-targeting epitope is capable of binding to a ligand binding domain of a nuclear steroid receptor.

25. The compound of claim 24, wherein the nuclear steroid receptor is an estrogen receptor, a glucocorticoid receptor, a progesterone receptor, or an androgen receptor.
26. The compound of any preceding claim, wherein the at least one nuclear receptor-targeting epitope binds to a nuclear steroid receptor with an IC_{50} of less than about 500 nM or an EC_{50} of less than about 1 μ M.
27. The compound of any preceding claim, wherein the at least one nuclear receptor-targeting epitope is not a peptide, protein, nanoparticle or antibody.
28. A compound as provided in Table 1.
29. A pharmaceutical composition comprising a compound as in any preceding claim and a pharmaceutically acceptable excipient.
30. A method for the treatment or prevention of a condition which can be ameliorated by inhibition of PARP in an individual in need thereof, the method comprising administering to the individual an effective amount of a compound or pharmaceutical composition of any preceding claim or a pharmaceutically acceptable salt or solvate thereof.
31. A method of treating or preventing cancer, comprising administering an effective amount of a compound or pharmaceutical composition of any preceding claim or a pharmaceutically acceptable salt or solvate thereof to an individual in need thereof.
32. The method of claim 30 or 31, wherein the administering comprises oral administration.
33. The method of any one of claims 30-32, further comprising administering an additional chemotherapeutic agent.
34. The method of claim 33, wherein the additional chemotherapeutic agent is cisplatin or etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, taxotere, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778123, BMS 214662, gefitinib, erlotinib hydrochloride, antibodies to EGFR, matatinib, intron, cytarabine, adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, vinblastine, vincristine, vindesine, bleomycin, doxorubicin, dactinomycin, daunorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide, 17 α -ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate, testolactone, megestrolacetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide, toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane,


mitoxantrone, levamisole, navelbene, anastrozole, letrozole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, avastin, herceptin, bexxar, velcade, zevalin, trisenox, xeloda, vinorelbine, porfimer, cetuximab, liposomal, Thiotepa, Altretamine, melphalan, Trastuzumab, lerozole, fulvestrant, exemestane, ifosfomide, rituximab, C225, Campath, carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP 16), tamoxifen, raloxifene, estrogen receptor binding agents, paclitaxel, gemcitabine, navelbine, farnesyl-protein transferase inhibitors, transplatinum, 5-fluorouracil, vincristine, vinblastine and methotrexate, or an analog or derivative thereof.

35. The method of any one of claims 31-34, further comprising administering radiotherapy to the patient.
36. The method of any one of claims 31-35, wherein the cancer is a BRCA positive cancer.
37. The method of any one of claims 31-35, wherein the cancer is a solid tumor.
38. The method of any one of claims 31-35, wherein the cancer is a cancer affecting B cells.
39. The method of any one of claims 31-38, wherein the cancer is a blood cancer, lung cancer, breast cancer, fallopian tube cancer, brain cancer, head and neck cancer, esophageal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer or skin cancer.
40. The method of claim 39, wherein the cancer is liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphomas, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoide, head neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, or prostatic carcinoma.
41. The method of claim 39, wherein the cancer is bladder cancer, breast cancer, fallopian tube cancer, ovarian cancer, prostate cancer, peritoneal cancer, testicular cancer, endometrial cancer, or uterine cancer.
42. A method of treating or preventing an androgen receptor overexpressing cancer, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt or solvate

CLAIMS

1. A compound of Formula, VB, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof:

IIIB IVA



wherein:


R² is -L-(B)_m;

m is 1, 2, or 3;

L is a covalent bond or a linking moiety; and

each B is independently a nuclear receptor-targeting epitope.

2. The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof wherein L is a non-biocleavable linking moiety.
- 5 3. The compound of any one of claim 1 or claim 2, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein L is an acid-labile linking moiety.
4. The compound of any one of claims 1-3, wherein the linking moiety is alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene or heterocycloalkylene; wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, may optionally comprise an arylene, heteroarylene, cycloalkylene or heterocycloalkylene; and further wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene or heterocycloalkylene is independently optionally substituted with one to five substituents independently selected from oxo, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkyl.
5. The compound of any one of claims 1-4, wherein the linking moiety is of the formula:



wherein:

each of Y¹, Y², and Y³ are independently a bond, -NR¹¹-, -O-, -S(O)₀₋₂-, -NR¹¹C(O)-, -C(O)NR¹¹-, -NR¹¹S(O)₂-, -S(O)₂NR¹¹-, -CR¹²=N-NR¹¹-, -NR¹¹-N=CR¹²-, -C(O)-, arylene, heteroarylene, cycloalkylene or heterocycloalkylene; wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene or heterocycloalkylene is independently optionally substituted with one to five substituents independently selected from oxo, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkyl;

each R¹¹ is independently C₁₋₄ alkyl, C₁₋₄ haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

each R¹² is independently C₁₋₄ alkyl, C₁₋₄ haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

n' and m' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

6. The compound of any one of the preceding claims, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein the at least one nuclear receptor-targeting epitope is a nuclear steroid receptor-targeting epitope.
7. The compound of any one of the preceding claims, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein the at least one nuclear receptor-targeting epitope is an estrogen receptor-targeting epitope,
8. The compound of any one of claims 1-6, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein the at least one nuclear receptor-targeting epitope is a glucocorticoid receptor-targeting epitope.
9. The compound of any one of claims 1-6, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein the at least one nuclear receptor-targeting epitope is a progesterone receptor-targeting epitope.
10. The compound of any one of claims 1-6, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein the at least one nuclear receptor-targeting epitope is an androgen receptor-targeting epitope.
11. The compound of any one of claims 1-6, , or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof wherein the at least one nuclear receptor-targeting epitope independently comprises an epitope derived from an androgen receptor agonist, an androgen receptor antagonist, a selective androgen-receptor modulator (SARM), an estrogen receptor agonist, an estrogen receptor antagonist, a selective estrogen receptor modulator (SERM), a glucocorticoid receptor antagonist, a glucocorticoid receptor agonist, a selective glucocorticoid receptor modulator (SGRM), a progesterone receptor


antagonist, a progesterone receptor agonist, a selective progesterone receptor modulator (SPRM), or a combination thereof.

12. The compound of any one of claims 1-6, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof wherein the at least one nuclear receptor-targeting epitope independently comprises an epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof, wherein each is modified to be conjugated to L.
13. The compound of any one of claims 1-6, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein at least one nuclear receptor-targeting epitope is capable of binding to a ligand binding domain of a nuclear steroid receptor.
14. The compound of claim 13, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein the nuclear steroid receptor is an estrogen receptor, a glucocorticoid receptor, a progesterone receptor, or an androgen receptor.
15. The compound of any one of the preceding claims, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof wherein the at least one nuclear receptor-targeting epitope binds to a nuclear steroid receptor with an IC_{50} of less than about 500 nM or an EC_{50} of less than about 1 μ M.
16. The compound of any one of the preceding claims, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof wherein the at least one nuclear receptor-targeting epitope is not a peptide, protein, nanoparticle or antibody.
17. A compound as provided in the following Table:

No.

Structure


1.1




No.

Structure


1.2




1.6




1.7




1.8




1.9



1.10




1.11




No.

Structure


1.12




1.13




1.14




1.15



1.16




1.17




No.

Structure


1.18




1.19




1.20




1.21



1.22




1.23




No.

Structure


1.61




1.62




1.63




1.64




1.65



1.66




1.67




No.

Structure


1.102




1.103




1.104




1.105



1.106




1.107




No.

Structure


1.108




1.109




1.110




1.111



1.112




1.113




No.

Structure


1.114




1.115




1.116



1.117




1.118




No.

Structure


1.119




1.120




1.121



1.122




1.123




No.

Structure


1.124




1.125




1.126




1.127



1.128




1.129




No.

Structure


1.135




1.136




1.137



1.138




1.139




No.

Structure


1.140




1.141




1.142



1.143




1.144




No.

Structure


1.145




1.146




1.147



1.148




1.149




No.

Structure


1.150




1.151




1.152



1.153




1.154




No.

Structure


1.166




1.167




1.168



1.169




1.176




No.

Structure


1.188




1.189




1.190



1.191




1.192




No.

Structure


1.193




1.210



1.211




1.212




No.

Structure


1.213



1.214




1.215




No.

Structure


1.216




1.217



1.234




1.235




No.

Structure


1.236




1.237




1.238



1.239




1.240




No.

Structure


1.241




1.242




1.243




2.1



2.2




2.3




No.

Structure


2.4




2.13




2.14



2.15




2.16




No.

Structure


2.17




2.18




2.19



2.20




2.21




No.

Structure


2.22




2.23




2.24



2.25




3.91




No.

Structure


3.104




3.105




3.106




3.121



3.122




3.136




No.

Structure


3.137




3.138




3.139



3.140




3.141




No.

Structure


3.142




3.143



3.144




3.145




No.

Structure


3.167




3.168



3.169




3.170




No.

Structure


3.182




3.183




3.184



3.185




3.202




No.

Structure


3.203




3.204




3.218



3.219




3.234




No.

Structure


3.235




3.236



3.241




3.242




No.

Structure


3.243




3.259



3.260



3.261



or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof.

18. A compound of any one of structures 1.1, 1.2, 1.6-1.23, 1.61-1.70, 1.82, 1.83, 1.86, 1.94-1.99, 1.101-1.159, 1.166-1.169, 1.176-1.179, 1.186-1.193, 1.210-1.217, 1.234-1.243, 2.1-2.4, 2.13-2.25, 3.91, 3.104-3.106, 3.121, 3.122, 3.136-3.150, 3.167-3.170, 3.182-3.185, 3.202-3.204, 3.218, 3.219, 3.234-3.236, 3.241-3.243, 3.259, 3.260, and 3.261 as in claim 17, or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising a compound as in any one of claims 1-17, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
20. Use of the compound or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof of any one of claims 1-17 in the manufacture of a medicament for the treatment of a condition which can be ameliorated by inhibition of PARP in an individual in need thereof.
21. Use of the compound or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof of any one of claims 1-17 in the manufacture of a medicament for treating cancer.

thereof, comprising at least one nuclear payload and at least one androgen receptor-targeting epitope to an individual in need thereof.

43. The method of claim 42, wherein the cancer is prostate, breast, triple negative breast cancer, bladder, or liver cancer.
44. The method of claim 42, wherein the androgen receptor-targeting epitope comprises an androgen receptor agonist, a selective androgen-receptor modulator (SARM), an androgen receptor antagonist, a selective estrogen receptor modulator (SERM), an estrogen receptor antagonist, a progestin, or an estrogen.
45. The method of claim 44, wherein the androgen receptor-targeting epitope comprises enobosarm, bicalutamide, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, estramustine, ketoconazole, abiraterone, darolutamide, or an analog thereof.
46. A method of treating or preventing an estrogen and/or progesterone receptor overexpressing cancer, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt or solvate thereof, comprising at least one nuclear payload and at least one estrogen and/or progesterone receptor-targeting epitope to an individual in need thereof.
47. The method of claim 46, wherein the cancer is breast, uterine, or ovarian cancer.
48. A method of treating or preventing a glucocorticoid receptor overexpressing cancer, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt or solvate thereof, comprising at least one nuclear payload and at least one glucocorticoid receptor-targeting epitope to an individual in need thereof.
49. The method of claim 48, wherein the cancer is prostate, breast, uterine, or ovarian cancer.